FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes

Ujas Parikh, Charles Marcus, Rutuparna Sarangi, Mehdi Taghipour, Rathan M. Subramaniam

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

Original languageEnglish (US)
Pages (from-to)327-343
Number of pages17
JournalPET Clinics
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2015

Keywords

  • <sup>18</sup>F-FDG PET/CT
  • Hepatocellular carcinoma
  • Pancreatic cancer

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes'. Together they form a unique fingerprint.

  • Cite this